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Abstract
Background: Neuroblastoma (NB) is the most frequently occurring solid tumor in children, and shows heterogeneous
clinical behavior. Favorable tumors, which are usually detected by mass screening based on increased levels of
catecholamines in urine, regress spontaneously via programmed cell death (PCD) or mature through differentiation into
benign ganglioneuroma (GN). In contrast, advanced-type NB tumors often grow aggressively, despite intensive
chemotherapy. Understanding the molecular mechanisms of PCD during spontaneous regression in favorable NB tumors,
as well as identifying genes with a pro-death role, is a matter of urgency for developing novel approaches to the treatment
of advanced-type NB tumors.
Principal Findings: We found that the expression of lysosomal associated protein multispanning transmembrane 5 (LAPTM5)
was usually down-regulated due to DNA methylation in an NB cell-specific manner, but up-regulated in degenerating NB
cells within locally regressing areas of favorable tumors detected by mass-screening. Experiments in vitro showed that not
only a restoration of its expression but also the accumulation of LAPTM5 protein, was required to induce non-apoptotic cell
death with autophagic vacuoles and lysosomal destabilization with lysosomal-membrane permeabilization (LMP) in a
caspase-independent manner. While autophagy is a membrane-trafficking pathway to degrade the proteins in lysosomes,
the LAPTM5-mediated lysosomal destabilization with LMP leads to an interruption of autophagic flux, resulting in the
accumulation of immature autophagic vacuoles, p62/SQSTM1, and ubiqitinated proteins as substrates of autophagic
degradation. In addition, ubiquitin-positive inclusion bodies appeared in degenerating NB cells.
Conclusions: We propose a novel molecular mechanism for PCD with the accumulation of autophagic vacuoles due to
LAPTM5-mediated lysosomal destabilization. LAPTM5-induced cell death is lysosomal cell death with impaired autophagy,
not cell death by autophagy, so-called autophagic cell death. Thus LAPTM5-mediated PCD is closely associated with the
spontaneous regression of NBs and opens new avenues for exploring innovative clinical interventions for this tumor.
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Introduction
Neuroblastoma (NB) is a malignant tumor consisting of
undifferentiated neuroectodermal cells from the neural crest and
the most common solid tumor in children. Most primary tumors
occur within the abdomen, with the adrenal medulla affected in
about 50% of NB patients [1–3]. The clinical behavior of NB is
heterogeneous: favorable tumors, which are usually detected by
mass screening based on increased levels of catecholamines in
urine, regress spontaneously via programmed cell death (PCD) or
mature through differentiation into benign ganglioneuromas (GN)
in patients under 1 year of age, with minimal or no therapeutic
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7099intervention; while advanced-type NBs, usually clinically detected,
often grow rapidly to become fatal in older children, despite
intensive chemotherapy [1–3].
The spontaneous regression and maturation of favorable NBs
coincide with the neuronal differentiation and massive cellular
suicide during the normal development of the nervous system,
indicating that NB cells in favorable tumors may retain the genetic
program of their normal counterparts [2]. Therefore, it has been
considered that NB cells within regressing tumors may undergo
apoptosis (a form of PCD), involving the neurotrophin signaling
pathway through TrkA (receptor) and nerve growth factor (NGF)
[3–9]. However some groups failed to find evidence of a
correlation between apoptosis and factors associated with
spontaneous regression [10–12]. On the other hand, a previous
electron microscopic analysis revealed that degenerative changes
including the accumulation of autophagic vacuoles are a
conspicuous feature of NBs [13], and it has also been proposed
that the spontaneous regression of NBs may occur via a H-Ras-
associated non-apoptotic mechanism with the appearance of
autophagic vacuoles in a caspase-independent manner [12]. Thus,
evidence suggests that both apoptosis and non-apoptotic cell death
play a role in the spontaneous regression of NBs [5].
The ‘‘wait and see’’ strategy has revealed that one third of mass-
screened NB tumors undergo spontaneous regression, and a
complete regression usually takes place over 4–20 months [4,14–
17]. This slow process suggests that the degenerating NB cells in
the late phase of PCD are a small proportion in favorable NB
tumors found by mass-screening and then exenterated surgically,
and therefore some genes having a pro-death role in PCD may yet
to be expressed in mass-screened NB tumor samples. To develop a
breakthrough in therapy against advanced-type NBs, which can
not regress spontaneously, it is important to identify genes having a
critical role in spontaneous regression/maturation and to
understand those molecular mechanisms.
Here, we found lysosomal associated protein multispanning transmem-
brane 5 (LAPTM5) to be closely associated with the spontaneous
regression of mass-screened NB tumors. Whereas the expression of
this gene was usually down-regulated through DNA methylation
in favorable and unfavorable NB tumor samples, it was up-
regulated in degenerating NB cells within locally regressing areas
of mass-screened tumors. Moreover, overexpression of this gene
induced caspase-independent lysosomal cell death due to lyso-
somal destabilization with lysosomal-membrane permeabilization
(LMP), with the accumulation of immature autophagic vacuoles
and ubiquitinated proteins, leading us to propose novel charac-
teristics for PCD during the spontaneous regression of NBs.
Results
Down-regulation of LAPTM5 expression through DNA
methylation in NB cells
Previously, we developed a DNA methylation-screening system,
bacterial artificial chromosome (BAC) array-based methylated
CpG island amplification (MCA) [18] (BAMCA) [19], and
identified tumor-related genes down-regulated through DNA
methylation in human cancers, including neuroblastoma [20–
22]. Using this system with an in-house ‘‘1p35–p36 contig BAC-
array’’ [19], we identified one BAC at 1p35 as potentially
methylated in NB cell lines, by comparing with two NB cell lines
(GOTO and IMR32) and a reference (normal peripheral blood
mononuclear cells, PBMNCs) (Supplementary Figure S1,
Supplementary Table S1, and Supplementary Methods
S1). Screening for two candidate genes (MATN1 and LAPTM5)o n
this BAC revealed that the expression of LAPTM5 was down-
regulated in NB cell lines and the CG sites around the
transcriptional start site (TSS) of this gene were highly and widely
methylated in both NB cell lines and primary NB tumors
(Supplementary Figure S1, Supplementary Table S1,
and Supplementary Methods S1), prompting us to focus on
LAPTM5 as a candidate for an NB-related gene down-regulated
through DNA methylation.
First, we examined the mRNA level, frequency of methylation,
and copy-number status of the LAPTM5 gene in 10 NB cell lines.
The expression of LAPTM5 was down-regulated in all the cell lines
and the down-regulation was inversely correlated with methylation
at the CG sites around the TSS, compared with normal adrenal
glands (Figure 1A and 1B), regardless of MYCN amplification or
allelic loss of LAPTM5 (Supplementary Figure S2, Supple-
mentary Table S2, and Supplementary Methods S1). In
addition, expression of LAPTM5 was restored in correlation with a
decrease of the methylation level after treatment with 5-aza-29-
deoxycytidine, a demethylating drug, in IMR32 and GOTO cells,
although the expression level of LAPTM5 after the restoration was
lower than that in normal adrenal glands (Figure 1A, 1B). We
next determined the mRNA level by quantitative RT-PCR and
the frequency of methylation at two CG sites (CG-I and –II)
upstream of TSS of LAPTM5 by the methylation-sensitive single
nucleotide primer extension (Ms-SNuPE) method in primary NB
tumors, including favorable (stage-1, -2, -3 and 4S) tumors
detected by mass screening and unfavorable (stage-4a) tumors
(Supplementary Figure S3). Methylation was detected in all
primary NB tumors examined and there was no significant
difference in mRNA level and methylation status among tumors at
each stage (Figure 1C). In addition, bisulfite sequencing revealed
that the CG sites around the TSS of LAPTM5 were highly and
widely methylated in NB tumors and frequently demethylated in
benign ganglioneuromas (GNs) that had developed from NB
tumors (Figure 1D). Notably, the frequency of methylation at the
two CG sites, especially CG-II, was significantly decreased in GNs
compared with NB tumors (66.4% to 43.0% for CG-I; p=0.0002,
50.3% to 20.9% for CG-II; p,0.0001; Figure 1E). Furthermore,
we examined the level of LAPTM5 protein in NB tumor sections
by conducting an immunohistochemical analysis using a specific
antibody and confirmed that the protein is highly expressed in
hematopoietic cells as reported [23] (Figure 1F). Although
LAPTM5 was also highly expressed in adjacent adrenal medulla
cells within the tumor sections and weakly expressed in
differentiated ganglion cells within GNs, its immunoreactivity in
NB cells was much lower, regardless of the prognosis (Figure 1F).
Taken together, these results suggested the expression of LAPTM5
to be epigenetically down-regulated through DNA methylation in
all NB cell lines and primary NB tumor samples and these
conditions to be associated with the differentiation of tumors.
Thus, the methylation and down-regulation of LAPTM5 may be
NB cell lineage-specific.
Up-regulation of LAPTM5 expression in degenerating NB
cells within regressing areas of mass-screened NB tumors
A focal regressing area is defined as a shrinking locus,
accompanied by gaps or clefts within a tumor section, which
occasionally appears in mass-screened NB tumors [12]. As shown
in Figure 2A, we found two types of regressing areas on
Hematoxylin-Eosin (HE) staining; type-I defined by a loss of cells
within the area including a number of differentiating NB cells with
an eosinophilic and large cytoplasm, and type-II defined by the
loss of a large group of undifferentiating NB cells. Interestingly,
our immunohistochemical analysis revealed the LAPTM5 protein
to be highly expressed in the NB cells within regressing areas (the
Mechanism of Tumor Regression
PLoS ONE | www.plosone.org 2 September 2009 | Volume 4 | Issue 9 | e7099Figure 1. Identification of methylated DNA and down-regulation of LAPTM5 expression in NB cell lines and primary NB tumors. (A)
LAPTM5 mRNA levels in NB cell lines with or without MYCN amplification (amp.) and/or allelic loss of the LAPTM5 gene were determined by
quantitative RT-PCR (qRT-PCR) and are indicated as bars. Levels of LAPTM5 mRNA were normalized with levels of GAPDH mRNA. GOTO and IMR32
cells were treated with 5-aza-29-deoxycytidine (5-aza-dC, 10 mM for 5 days). (B) Frequencies of methylation at 17 CG sites within region-I around the
transcriptional-start site (TSS) of the LAPTM5 gene were determined by bisulfite sequencing, as indicated in Supplementary Figure S1. An arrow
indicates the TSS. (C) Methylation frequency and mRNA level of LAPTM5 in primary NB tumors at different stages. Levels of LAPTM5 mRNA measured
by qRT-PCR are indicated as dots; whereas methylation frequencies at two CG sites (CG-I or –II) measured by Ms-SNuPE are indicated as dark gray and
light bars, respectively. Levels of LAPTM5 mRNA were normalized with levels of GAPDH mRNA. n indicates the number of cases. Vertical lines, SD. (D)
Representative results of bisulfite sequencing at CG sites around the TSS of LAPTM5 in primary NB tumors and ganglioneuromas (GNs). Methylation
status is indicated as white (unmethylated) or black (methylated) circles. An arrow indicates the TSS. (E) Methylation frequency of LAPTM5 in primary
NB tumors and GNs. The methylation frequencies at two CG site in 8 GNs were measured by Ms-SNuPE. The average frequency of methylation in
primary NB tumors or GNs is indicated. n indicates the number of cases. Vertical lines, SD. (F) Representative images of immunostaining for LAPTM5 in
tissue sections. Upper; representative images of hematopoietic cells, adrenal tissue within tumor sections, and GN. The enlarged image shows the
adrenal medulla cells within adrenal tissue indicated by arrowheads. Lower; representative images of NB cells within a favorable tumor (stage-1)
detected by mass-screening and an advanced-type tumor (stage-4a) with MYCN amplification.
doi:10.1371/journal.pone.0007099.g001
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report [12] that H-Ras was also highly expressed in such areas
(Supplementary Figure S4). Notably, while LAPTM5 was
weakly expressed in the differentiating NB cells within type-I
regressing areas, it appeared to be accumulated in the degener-
ating NB cells within type-I and –II regressing areas, compared
with that in differentiating NB cells, adrenal medulla cells, or
ganglion cells in GNs (Figure 1F and Figure 2A). These
Figure 2. Immunostaining of LAPTM5 protein in degenerating NB cells within regressing area in mass-screened NB tumors. (A) Serial
tumor sections were stained with hematoxylin-eosin (HE) (a, b, e, and f) or with anti-LAPTM5 (c, d, g, and h). a–d; representative image of a type-I
regressing area, with a loss of cells including differentiating NB cells. e–h; representative image of a type-II regressing area, with a large loss of
undifferentiated NB cells. The images of b, d, f, and h are the areas enlarged by the rectangle in a, c, e, and g, respectively. The area surrounded with
arrowheads in a and e indicates a typical regressing area. In d and h images, arrowheads and arrows indicate differentiating NB cells and
degenerating NB cells, respectively. (B) Relationship of between LAPTM5-associated regression with patients and tumor characteristics. A comparison
was made of the proportion of positive cases between mass-screened NBs and clinically detected NBs. The stage of each tumor was determined
using the INSS (International Neuroblastoma Staging System). NA; cases with MYCN amplification. (C) Representative image of immunostaining of
cleaved caspase-3. SH-SY5Y cells with or without treatment with Cisplatin (CDDP; 1.5 mg/ml) for 2 days or serial tumor sections were stained with an
antibody to cleaved caspase-3 antibody.
doi:10.1371/journal.pone.0007099.g002
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were much more frequently observed in the mass-screened NB
tumors (42 of 54 tumors, 77.8%), than in the clinically detected
NB tumors (1 of 17 tumors, 5.9%) (Figure 2B). Furthermore, only
one clinically detected tumor with LAPTM5-positive degenerating
areas was classified as favorable (stage-2, well-differentiating). In
addition, the immunostaining of cleaved caspase-3 revealed that
LAPTM5-positive degenerating NB cells were essentially negative
at least when the cleaved caspase-3 was present in SH-SY5Y cells
induced into apoptosis by treatment with Cisplatin (CDDP)
(Figure 2C), suggesting that caspase-independent cell death might
occur in LAPTM5-positive degenerating NB cells. We further
confirmed that the hematopoietic cells expressing the CD20
antigen (BCA-B20) specific for normal peripheral B lymphocytes
could not be detected within the regressing areas of mass-screened
NB tumors (Supplementary Figure S4). Those results suggest
that the expression of LAPTM5 is closely associated with the
spontaneous regression of mass-screened NB tumors and the
accumulation of this protein rather than the restoration of its
expression contributes to the PCD of NB cells in a caspase-
independent manner.
LAPTM5 overexpression induces caspase-independent
cell death and the accumulation of this protein is
required to induce cell death in NB cell lines
To examine whether LAPTM5 contributes to the PCD of NB
cells, the protein was overexpressed in NB cell lines using an
adenovirus-mediated expression system. Strong expression of the
LAPTM5 protein was detected at 4 days, rather than at 2 days,
after infection in three cell lines, GOTO, IMR32, and SH-SY5Y
(Figure 3A), and cell survival rates decreased in a dose-dependent
manner on adenovirus-LAPTM5 (Ad-LAPTM5) infection
(Figure 3B). Moreover, a remarkable increase in the number of
dead cells with an increase in LAPTM5 protein level was observed
at 4 days, after infection with Ad-LAPTM5, compared with
adenovirus-LacZ (Ad-LacZ), in all cell lines. The cell death
induced by Ad-LAPTM5 infection was not inhibited by treatment
with 100 mM of zVAD-fmk, a pan-caspase inhibitor, although the
reduction of cell viability induced by CDDP was partially inhibited
by treatment with the same concentration of zVAD-fmk in SH-
SY5Y cells (Figure 3C and Supplementary Figure S5). In
addition, on immunostaining and western blotting, we detected
almost no cleaved caspase-3 in Ad-LAPTM5-infected NB cell lines
(Supplementary Figure S5), and found none of the typical
features of apoptosis, such as nuclear fragmentation and apoptotic
bodies during LAPTM5-induced cell death (data not shown).
These results suggest that overexpression of LAPTM5 mainly
induces a non-apoptotic cell death in a caspase-independent
manner in NB cells.
Based on the immunohistochemical observations that LAPTM5
seemed to be markedly accumulated in degenerating NB cells,
together with the observation in vitro that no cell death was
detected at 2 days after infection regardless of the expression of
LAPTM5, we speculated that the protein accumulated due to a
decrease in turnover efficiency for degradation and its accumu-
lation is required to induce cell death. To test this idea, we first
investigated whether LAPTM5 was accumulated on treatment
with inhibitors for the intracellular protein degradation system
(proteasomal or lysosomal degradation). When GOTO cells at 1
day after Ad-LAPTM5 infection were treated with a proteasomal
inhibitor (ALLN or MG132) or a lysosomal inhibitor (Bafilomycin
A1; Baf.A1 or NH4Cl) for 1 day, a remarkable accumulation of
LAPTM5 was detected by western blotting, compared with that in
Ad-LAPTM5-infected GOTO cells without each of these
treatments (Figure 3D). In addition, we showed that the
induction of cell death was significantly enhanced in correlation
with the accumulation of LAPTM5 in Ad-LAPTM5-infected
GOTO cells treated with Baf.A1, compared to Ad-LAPTM5-
infected GOTO cells without Baf.A1-treatment or in Ad-LacZ-
infected GOTO cells treated with Baf.A1 (p=0.027 or p=0.042)
or with ALLN, compared to Ad-LAPTM5-infected GOTO cells
without treatment or Ad-LacZ-infected GOTO cells treated with
ALLN (p=0.022 or p=0.028) (Figure 3E). Moreover, we
examined the effect of inhibiting the accumulation of LAPTM5
with specific siRNA to confirm that the accumulation is required
for the induction of cell death. When LAPTM5 siRNA-transfected
GOTO cells were infected with Ad-LAPTM5, and cultured with
or without Baf.A1 or ALLN, a remarkable inhibition of
LAPTM59s accumulation was confirmed by western blotting
(Figure 3F). In this setting, the frequency of dead cells was
significantly decreased in LAPTM5 siRNA-transfected GOTO
cells, compared with that in control siRNA-transfected GOTO
cells (p=0.035 for Baf.A1; p=0.022 for ALLN) (Figure 3G).
Taken together, these results indicate that the introduced
LAPTM5 is usually degraded by both proteasomal and lysosomal
pathways and the accumulation of this protein is critical for the
induction of cell death.
Appearance of autophagic vacuoles during LAPTM5-
induced cell death
Non-apoptotic cell death in a caspase-independent manner is
often accompanied by the appearance of numerous autophagic
vacuoles in the cytoplasm [23], and has been proposed as one of
the mechanisms for PCD during the spontaneous regression of NB
tumors [12,13]. We therefore examined whether autophagic
vacuoles appear in the cytoplasm during LAPTM5-induced cell
death. Electron microscopic analysis revealed numerous autoph-
agic vacuoles in the cytoplasm of most Ad-LAPTM5-infected
GOTO cells, as compared with Ad-LacZ-infected cells
(Figure 4A). In addition, when GOTO cells stably expressing
GFP-LC3 and the parental GOTO cells were infected with Ad-
LAPTM5, as well as when the cells were starved to activate
autophagic flux, a remarkable increase in cells showing a
punctuate distribution of GFP-LC3 or endogenous LC3B was
observed by immunofluorescence microscopy, compared with
untreated cells or Ad-LacZ-infected cells, respectively (p=0.0022
in GOTO cells stably expressing GFP-LC3, p=0.0288 in parental
GOTO cells) (Figure 4B) [23,24]. Moreover, the cleaved form
(LC3B-II) for endogenous LC3B, another indicator of the presence
of autophagic vacuoles, was also clearly detected in GOTO cells
during LAPTM5-induced cell death as well as starved cells by
western blotting (Figure 4C) [23,24]. Similar results were
observed in Ad-LAPTM5-infected GOTO cells stably expressing
GFP-LC3 (Supplementary Figure S6). In addition, the cleaved
form and a punctuate distribution for endogenous LC3B were
observed during LAPTM5-induced cell death in SH-SY5Y cells
(Supplementary Figure S6). These findings indicate that
overexpression of LAPTM5 induces cell death with the appear-
ance of autophagic vacuoles in NB cells.
Appearance of autophagic vacuoles during LAPTM5-
induced cell death is attributed to an interruption of
autophagic flux
The autophagic process functions as a flux, with portions of the
cytosol and intracellular organelles sequestered into the autopha-
gosome. The autophagosome fuses with intracellular vesicles and
finally matures into the autolysosome through fusion with the
Mechanism of Tumor Regression
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While the autophagic process is rapidly activated in the absence of
nutrients for cell survival, the process also occurs constitutively at a
low level in cells (basal autophagic flux) [23,24]. Importantly, the
appearance of numerous autophagic vacuoles during cell death
does not necessarily reflect ‘‘so-called autophagic cell death’’
Figure 3. Induction of caspase-independent cell death by LAPTM5 overexpression and effect of LAPTM5 accumulation on the cell
death. (A) Western blot analysis of adenovirus-infected GOTO, IMR32, and SH-SY5Y cells. The cells were infected with the LacZ (Ad-LacZ) or LAPTM5
(Ad-LAPTM5) adenovirus at a MOI of 10 for GOTO and SH-SY5Y or 4 for IMR32. Two and four days after infection, whole-cell lysates was isolated, and
analyzed by immunoblotting with an antibody to LAPTM5 or b-actin (internal control). Results shown are representative of two independent
experiments. (B) Viability of adenovirus-infected GOTO, IMR32, and SH-SY5Y cells. GOTO (5610
4 cells/well), IMR32 (2610
4 cells/well), or SH-SY5Y
(5610
4 cells/well) cells plated in 24-well plates were infected with Ad-LacZ or Ad-LAPTM5 at the indicated MOIs. Four days after infection, the
percentage of surviving cells was determined by a colorimetric water-soluble tetrazolium salt (WST) assay. Vertical lines, SD for three experiments. No
inf., no infection. (C) Frequency of dead cells among adenovirus-infected GOTO, IMR32, and SH-SY5Y cells. The cells were infected with Ad-LacZ or
Ad-LAPTM5 under the same conditions as in (A) with or without treatment with the pan-caspase inhibitor zVAD-fmk at 100 mM in each cell line. Dead
cells were counted 2 and 4 days after infection using the trypan blue exclusion method, and indicated as percentages. Vertical lines, SD for three
experiments. (D) Western blot analysis of LAPTM5 in LAPTM5-infected GOTO cells treated with protein degradation inhibitors. Cells were infected
with Ad-LacZ or Ad-LAPTM5 at a MOI of 10. One day after infection, cells were treated with Bafilomycin A1 (Baf.A1, lysosomal inhibitor), NH4Cl
(lysosomal inhibitor), ALLN (proteasome inhibitor), or MG-132 (proteasome inhibitor) at indicated concentration for 1 day. Whole-cell lysate was
analyzed by immunoblotting with indicated antibodies. The results shown represent two independent experiments. (E) Frequency of dead cells
among LAPTM5-infected GOTO cells treated with protein degradation inhibitors. Cells were infected and treated with Baf.A1 or ALLN, as indicated in
(D). Dead cells were counted using the trypan blue exclusion method, and indicated as percentages. Vertical lines, SD for three experiments. *t-test;
p,0.05. (F) Western blot analysis of LAPTM5 inhibition by siRNA transfection in LAPTM5-infected GOTO cells treated with protein degradation
inhibitors. Cells were transfected with control- or LAPTM5-siRNA, and infected with Ad-LacZ or -LAPTM5 at a MOI of 10. The next day cells were
treated with the inhibitor Baf.A1 or ALLN for 1 day. Whole-cell lysate was analyzed by immunoblotting with indicated antibodies. The results shown
represent two independent experiments. (G) Effect of siRNA transfection on frequency of dead cells among LAPTM5-infected GOTO cells treated with
protein degradation inhibitors. Cells were infected and treated with Baf.A1 or ALLN, as indicated in (F). Dead cells were counted using the trypan blue
exclusion method, and indicated as percentages. Vertical lines, SD for three experiments. *t-test; p,0.05.
doi:10.1371/journal.pone.0007099.g003
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7099Figure 4. Appearance of autophagic vacuoles during LAPTM5-induced cell death. (A) Representative transmission-electron micrographs
of Ad-LacZ (a) or Ad-LAPTM5 (b and c) -infected GOTO cells 4 days after infection. The (c) image was enlarged from the area enclosed by the
rectangle in (b), showing the accumulation of autophagic vacuoles (arrowheads). (B) Localization of GFP-LC3 or endogenous LC3B detected by
immunofluorescence microscopy. GOTO cells stably expressing GFP-LC3 (1610
5/well) (upper panel) or parental GOTO cells (1610
5/well) (lower panel)
were plated on coverslips in 24-well plates, and the next day infected with Ad-LacZ or Ad-LAPTM5 at a MOI of 10. Four days later, the GOTO cells
stably expressing GFP-LC3 were fixed in 4% formaldehyde, and observed under a fluorescence microscope. For parental GOTO cells, the cells were
fixed in 10% TCA 4 days after infection, reacted with the LC3B antibody, and visualized with an FITC-conjugated secondary antibody. Control cells
starved of nutrients were treated with EBSS for 2 hours at 5 days of plating. The frequency of cells with a punctate distribution (dot pattern) of GFP-
LC3 or LC3B among all GFP-positive cells or total cells (at least 200 cells), respectively, was measured. *t-test, p,0.005 and **p,0.05. Vertical lines, SD
for three experiments. (C) Detection of LC3B-II by western blotting. As the time-courses indicated, whole-cell lysate from GOTO cells starved of
nutrients or infected with Ad-LacZ and Ad-LAPTM5 at a MOI of 10 was analyzed by immunoblotting with an antibody to endogenous LC3B or b-actin
(internal control). Arrows indicate form-I or -II of LC3B. Results shown are representative of two independent experiments.
doi:10.1371/journal.pone.0007099.g004
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formation of autophagosomes was inhibited by treatment with
wortmannin, an autophagic inhibitor, or by the knockdown of
ATG5 expression during cultivation in a starved state or
LAPTM5-induced cell death in GOTO cells, the number of cells
showing a punctate pattern of LC3B expression was significantly
decreased (Figure 5A and Supplementary Figure S7). Even
though the autophagic process was experimentally inhibited, the
Figure 5. Interruption of autophagic flux during LAPTM5-induced cell death. (A) Effect of treatment with wortmannin or transfection with
ATG5 siRNA in GOTO cells with a punctate distribution of LC3B. Cells (1610
5/well) were plated on coverslips in 24-well plates and the next day treated
with wortmannin (Wort.; 200 nM) or DMSO (0.02%), or transfected with ATG5 siRNA (20 nM) or Luciferase siRNA (20 nM). Left; 4 days after the
treatment or transfection, cells were treated with EBSS for 2 hours. Right; the plated cells were infected with Ad-LacZ or Ad-LAPTM5 at a MOI of 10 for
4 days with treatment with DMSO or wortmannin, or with transfection with Luciferase or ATG5 siRNA. Then, cells were fixed in 10% TCA, reacted with
the LC3B antibody, and visualized with an FITC-conjugated secondary antibody. Upper; western blotting analysis of ATG5. Whole-cell lysate was
analyzed by immunoblotting with an antibody to ATG5 or b-actin (internal control). Lower; frequency of cells showing a punctate distribution of LC3B
among cells (at least 200 cells) was measured. *t-test, p,0.001 and **p,0.01. Vertical lines, SD for three experiments. (B) Effect of treatment with
wortmannin or the knockdown of ATG5 during LAPTM5-induced cell death. GOTO cells (1610
4/well) were plated in 96-well plates and infected with
Ad-LacZ or LAPTM5 at a MOI of 10 with treatment with DMSO or wortmannin (Wort.), or with transfection with Luciferase or ATG5 siRNA. Four days
after infection, numbers of viable cells were assessed by WST assay. Vertical lines, SD for three experiments. (C) Western blot analysis of p62/SQSTM1
and ubiquitin in LAPTM5-infected GOTO cells. The same whole-cell lysates indicated in Figure 3A were analyzed by immunoblotting with indicated
antibodies. The results shown represent two independent experiments. (D) Immunofluorescence microscopy for p62/SQSTM1 and ubiquitin in
LAPTM5-infected GOTO cells. Upper; GOTO cells (1610
5/well) were plated on coverslips in 24-well plates, and infected with Ad-LAPTM5 at a MOI of
10. Four days after infection, the cells were fixed in 4% formaldehyde, reacted with p62/SQSTM1 and ubiquitin antibodies, and visualized with an
FITC- or Alexa Fluor 594-conjugated secondary antibody. Arrowheads indicate the cells with p62/SQSTM1-ubiquitin positive inclusion-like body. DAPI
was used for counterstaining. (E) Western blotting of ubiquitinated proteins. Four days after infection, GOTO cells were lysed in a 0.1% Triton-X
solution. The Triton-insoluble pellet (P) was lysed in a 2% SDS buffer. The Triton-X soluble (S) or -insoluble (P) lysate was loaded on a 6% SDS-PAGE gel
and analyzed by immunoblotting with an antibody to ubiquitin or a-tublin. For both soluble and insoluble samples, ubiquitinated proteins were
found to be accumulated in Ad-LAPTM5-infected GOTO cells, compared with Ad-LacZ-infected GOTO cells. The results shown represent two
independent experiments.
doi:10.1371/journal.pone.0007099.g005
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(Figure 5B), indicating that LAPTM5-induced cell death is not
‘‘so-called autophagic cell death’’ [23] and the appearance of
autophagic vacuoles during LAPTM5-induced cell death may
result in the accumulation of immature autophagic vacuoles due to
an interruption of basal autophagic flux.
Accumulating evidence suggests that p62/SQSTM1 and some
ubiquitinated proteins are degraded during the autophagic process
by which p62/SQSTM1 recruits ubiquitinated proteins into the
autophagosome through interaction directly with LC3 protein to
be degraded by autophagy [24–26]. In addition, the genetic
disruption of autophagic flux in mouse neurons led to the
accumulation of p62/SQSTM1 and ubiquitinated proteins and
the formation of inclusion bodies with these proteins, resulting in a
loss of neurons by cell death [27,28]. To further confirm that basal
autophagic flux is interrupted during LAPTM5-induced cell
death, we examined levels of p62/SQSTM1 protein and
ubiquitinated proteins. As expected, a remarkable accumulation
of both p62/SQSTM and ubiquitinated proteins was observed on
western blotting (Figure 5C) and immunofluorescence analysis
(Supplementary Figure S8). These proteins were frequently
co-localized as inclusion-like bodies (Figure 5D) and ubiquiti-
nated protein levels were increased in the Triton-X insoluble
fraction, not only the soluble fraction, in Ad-LAPTM5-infected
GOTO cells (Figure 5E). We also confirmed that p62/SQSTM
and GFP-LC3 were occasionally co-localized to cytoplasmic spots
(or ring-like structures) as autophagosomes in Ad-LAPTM5-
infected GOTO cells (data not shown). These findings strongly
suggest that overexpression of LAPTM5 leads to an interruption of
basal autophagic flux, and results in the accumulation of p62/
SQSTM1 and ubiqutinated proteins, as well as of immature
autophagic vacuoles, that is, ‘‘cell death with impaired autophagy’’
[23].
Accumulation of LAPTM5-positive vesicles during
LAPTM5-induced cell death
LAPTM5 is a multispanning transmembrane protein that
resides in lysosomes [29]. Further, it has been demonstrated that
LAPTM5 contributes to vesicle trafficking from the Golgi
apparatus to the lysosome [30]. Therefore, we investigated the
subcellular distribution of LAPTM5 in cells together with that of
Golgi-58K (Golgi marker) or LAMP2 (Lysosome marker) by
conforcal microscopy. As shown in Figure 6A, the exogenously
expressed LAPTM5 was localized to vesicles and exhibited a
punctuate pattern, and the LAPTM5-positive vesicles did not
colocalize with the Golgi apparatus, but partially colocalized with
LAMP2-positive lysosomes 1 day after the infection with Ad-
LAPTM5. Four days after the infection, LAPTM5-positive vesicles
were remarkably accumulated as larger entities in dying cells and
colocalized with neither the Golgi apparatus nor LAMP2-positive
lysosomes. Rather, Golgi-58K-positive structures and LAPM-2-
positive punctuate pattern were shown to be reduced in dying cells
with a strong accumulation of LAPTM5-positive vesicles.
Since treatment with lysosomal or proteasomal-degradation
inhibitors significantly enhanced LAPTM5-induced cell death
combined with the accumulation of exogenously expressed
LAPTM5 (Figure 3D and 3E), we next examined the subcellular
localization of accumulated LAPTM5 under such conditions.
LAPTM5 protein was remarkably accumulated as large vesicles in
Ad-LAPTM5-infected GOTO cells treated with 10 nM Baf.A1 or
10 mM ALLN (Figure 6B) for one day, similar to the pattern
observed 4 days after the infection with Ad-LAPTM5 (Figure 6A).
In addition, a reduction in Golgi-58K-positive structure and
LAPM-2-positive punctuate pattern was also observed in dying
cells with a strong accumulation of LAPTM5-positive vesicles.
Alternatively, when GOTO cells were infected with Ad-LAPTM5
for 2 days under mild treatment with 2 nM of Baf.A1 or 2 uM of
ALLN, LAPTM5-positive vesicles were frequently co-localized
with LAMP2-positive lysosomes (Supplementary Figure S9).
Based on the these findings, it is considered that LAPTM5
intrinsically localizes to trafficking vesicles from Golgi to lysosomes
in NB cells, and an increase of LAPTM5 protein leads to the
production of LAPTM5-positive vesicles. Further the gradual
accumulation of these vesicles by consecutive overexpression of
LAPTM5 and/or a treatment with lysosomal or proteasomal
inhibitor leads to losses of the Golgi apparatus and punctate
pattern of lysosomes. Consequently, the accumulation of
LAPTM5-positive vesicles might lead to lysosomal destabilization.
Induction of lysosomal destabilization with lysosomal-
membrane permeabilization (LMP) during LAPTM5-
induced cell death
Based on the results of the immunofluorescence analysis
(Figure 6), we examined whether lysosomal destabilization occurs
during LAPTM5-induced cell death. Along with the loss of a
punctuate pattern of LysoTracker Rhodamine (LTR) staining
(Pale cells) which reflects lysosomal destabilization via lysosomal-
membrane permeabilization (LMP) [31–35], we observed the loss
of the punctuate pattern in proportion to an increase in cell death
among LAPTM5-infected GOTO cells (2.7-fold in GOTO,
p=0.0007, compared with Ad-LacZ; Figure 7A and Supple-
mentary Figure S10). In addition, we found a diminution in
acridine orange (AO) uptake [31], another indicator for LMP,
during LAPTM5-induced cell death, in a FACS analysis
(p=0.0001 in Ad-LAPTM5-infected GOTO cells compared to
those infected with Ad-LacZ; Figure 7B). Since lysosomal
destabilization with LMP leads to the leakage of enzymes from
the lysosome into the cytosol, we examined the subcellular
distribution of cathepsin D (CTSD), a lysosomal enzyme [32].
The number of cells leaking CTSD into the cytosol was
significantly increased among Ad-LAPTM5-infected GOTO cells
compared with Ad-LacZ-infected GOTO cells (p=0.0388)
(Figure 7C). In addition, we also observed that the fluorescein
isothiocyanate-labelled dextran (FITC-dextran; 40kD), which was
incorporated intact lysosomes, also was leaked into the cytosol
(Supplementary Figure S10 and Supplementary Methods
S1) [31]. Moreover, treatment with ciprofloxacin (CPX), a known
inducer of LMP [30], also resulted in the presence of the GFP-
LC3-II form and the accumulation of p62/SQSTM1 proteins
(Supplementary Figure S11). Taken together, these findings
suggest the accumulation of LAPTM5 in NB cells to cause
lysosomal cell death due to lysosomal destabilization with LMP.
The lysosomal dysfunction caused by LAPTM5-mediated LMP
might lead to an interruption to basal autophagy flux, probably
resulting in the increased number of immature autophagic
vacuoles.
To confirm whether levels of CTSD, p62/SQSTM1, and
ubiqutinated proteins are increased in degenerating NB cells as
observed in vitro, we performed an immunohistochemical analysis
using each specific antibody in primary NB tumors. As shown in
Figure 7D, levels for each of these proteins were remarkably
increased in degenerating NB cells within regressing areas,
compared with levels in non-degenerating NB cells, in the mass-
screened NB tumors. Notably, ubiquitin-positive inclusion bodies
were occasionally observed in degenerating NB cells. In addition,
the CTSD protein appeared to fill the cytoplasm. These
observations suggest that degenerating NB cells accumulating
LAPTM5 protein undergo lysosomal cell death with LMP and
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PLoS ONE | www.plosone.org 9 September 2009 | Volume 4 | Issue 9 | e7099Figure 6. Localization of accumulated LAPTM5 during LAPTM5-induced cell death. (A) Representative image of the co-staining of Golgi-
58K or LAMP2 (Green) and LAPTM5 (Red). GOTO cells (1610
5/well) were plated on coverslips in 24-well plates and the next day infected with Ad-LacZ
or Ad-LAPTM5 at a MOI of 10. One or four days after infection, the cells were fixed in 10% TCA, reacted with Golgi-58K or LAMP2 and LAPTM5
antibodies, and visualized with FITC- or Alexa Fluor 594-conjugated secondary antibodies. DAPI was used for counterstaining. Arrowheads indicate
the cells with a loss of Golgi apparatus structures. (B) Representative image of the co-staining of Golgi-58K or LAMP2 (Green) and LAPTM5 (Red).
GOTO cells were infected with Ad-LacZ or Ad-LAPTM5 a MOI of 10, and next day treated with Bafilomycin A1 (Baf.A1) or ALLN for 1 day. Arrowheads
indicate the cells with a loss of Golgi apparatus structures. Then immunofluorecent images were obtained as in (A).
doi:10.1371/journal.pone.0007099.g006
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PLoS ONE | www.plosone.org 10 September 2009 | Volume 4 | Issue 9 | e7099Figure 7. Induction of lysosomal-membrane permeabilization (LMP) during LAPTM5-induced cell death. (A) Representative images of
LysoTracker Rhodamine (LTR) staining in infected GOTO cells. GOTO cells (1610
5/well) were plated on coverslips in 24-well plates, and infected with
Ad-LAPTM5 at a MOI of 10. Four days after infection, cells were stained with LTR (100 nM) for 30 min at 37uC, washed twice and fixed in 4%
formaldehyde, and observed by fluorescence microscopy. (B) Acridine orange (AO) uptake analysis in infected GOTO cells. GOTO cells (2610
5/well)
were plated in 6 well plates, and infected with Ad-LAPTM5 at a MOI of 10. Four days later, cells were stained with AO (5 mg/ml, 30 min). Detached
cells were removed, and attached cells were collected by trypsinization and washed twice with PBS. Left-upper; scatter blots of FSC and SSC for Ad-
LacZ or Ad-LAPTM5-infected cells. The main population of cells was gated and analyzed by FACS. Left-lower; the intensity of staining was measured
by FACS using a channel of FL3; the range containing .99% of the cells without AO fluorescence was gated. Black line indicates Ad-LAPTM5-infected
cells; red line, Ad-LacZ-infected cells. The frequency of cells with a reduction in AO staining was increased among Ad-LAPTM5-infected GOTO cells.
Right; percentage of cells with a reduction in AO fluorescence. Vertical lines, SD for four separate experiments. *t-test, p,0.01. (C) Representative
images of staining for cathepsin D (CTSD) in infected GOTO cells. GOTO cells (1610
5/well) were plated on coverslips in 24-well plates, and the next
day infected with Ad-LacZ or Ad-LAPTM5 at a MOI of 10. Four days after infection, the cells were fixed in 10% TCA, reacted with a CTSD antibody, and
visualized with an Alexa Fluo 594-conjugated secondary antibody. The percentage of cells that released CTSD (arrow) was measured. Vertical lines, SD
for three separate experiments. *t-test, p,0.05. (D) Representative images of staining for CTSD, p62/SQSTM1, or ubiquitin in non-regressing or
regressing areas within favorable NB tumors. Serial tumor sections were stained with each antibody. The area enclosed by the rectangle is enlarged at
the right. Arrows indicate cells with ubiquitin-positive inclusion bodies.
doi:10.1371/journal.pone.0007099.g007
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PCD of NB cells during the spontaneous regression of favorable
NB tumors.
Discussion
In the present study, the BAMCA method revealed that
LAPTM5 was highly methylated and its expression was transcrip-
tionally down-regulated in NB cell lines. Unexpectedly, the
methylation/down-regulation of this gene was detected in all the
primary NB tumors and cell lines examined, and we further could
detect no difference in methylation status and expression level
between favorable and unfavorable NB tumors. Based on our
findings that the mRNA level of LAPTM5 restored after treatment
with 5-aza-dC was still lower than in normal adrenal glands and
the frequency with which LAPTM5 was methylated was decreased
in benign GNs, we conclude that the methylation of LAPTM5 in
NB cells is not aberrant methylation for an irreversible shut-off of
the expression as occurs in CpG islands of classical tumor
suppressor genes (indeed LAPTM5 has no CpG islands) and may
contribute to maintaining a constitutively down-regulated state
and/or prevent leaking of the expression of this gene under
conditions without transcriptional activation in an NB cell lineage-
specific manner. Indeed, a recent report also found a decrease in
the methylation of LAPTM5 during normal lung development and
in correlation with the differentiation state of lung tumors [36].
One key finding of the present study is that LAPTM5-mediated
programmed cell death (PCD) was closely associated with the
spontaneous regression of mass-screened NB tumors. As illustrated
in Figure 8, although LAPTM5 expression usually appears to be
down-regulated through DNA methylation in both favorable and
unfavorable NBs, it is up-regulated in degenerating NB cells within
locally limited regressing areas of favorable NBs. Our immuno-
histochemical analyses revealed that LAPTM5-positive degener-
ating NB cells were frequently detected in mass-screened NB
tumors, but not in clinically detected unfavorable tumors,
establishing a clear correlation between LAPTM5-mediated
PCD and the propensity of NB tumors to undergo regression.
The mass-screened NB tumors contained LAPTM5-positive
degenerating NB cells, nonetheless we could not detect a
significant difference in the mRNA expression of this gene
between favorable and unfavorable tumor samples, suggesting
the up-regulation of LAPTM5 expression to be involved in the
pro-death role in the late phase of PCD in regressing tumors and
LAPTM5-positive degenerating NB cells are a small proportion in
mass-screened NB tumors.
Our observations also revealed that the LAPTM5 protein to be
more significantly accumulated in degenerating NB cells than
differentiating NB cells and the accumulation to be required to
induce cell death in NB cells. Our in vitro study showed that the
consecutive overexpression of LAPTM5 led to the accumulation of
LAPTM5-positive vesicles and the accumulation was enhanced by
treatment with inhibitors for either the lysosomal or proteasomal
pathway. Moreover, under cellular stress caused by treatment with
a neurotoxin (such as 1-methyl-4-phenylpyridinium; MPP
+)o r
H2O2, or on cell differentiation induced by treatment with retinoic
acid (RA), we found a remarkable increase of LAPTM5 expression
at the transcriptional level. In addition, we showed an accumu-
lation of LAPTM5 protein level in RA-induced differentiated
IMR32 cells treated with Baf.A1 or ALLN (Supplementary
Figure S12 and Supplementary Methods S1). Thus, the
results suggest that lysosomal or proteosomal degradation of
LAPTM5, whose impairment might enhance the accumulation of
the protein and/or LAPTM5-positve vesicles, in addition to the
Figure 8. Model of the relationship between LAPTM5-mediated degeneration and propensity for spontaneous regression of NB
tumors.
doi:10.1371/journal.pone.0007099.g008
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stress, also plays a critical role in degeneration and cell death in
NB cells. Indeed, the spontaneous regression of clinically favorable
NB tumors is known to occur over a period of several months
[4,14–17].
Advanced-type NB tumors are presumed to have a very low
chance of regressing, and the final outcome for any NB tumor is
likely to be attributable to cytogenetic aberrations as well as
biological differences [1–3]. Deletion of the short arm of
chromosome 1 (1p), observed in about 40% of NBs, is strongly
associated with a poor prognosis, and highly associated with
MYCN amplification, which is itself a strong indicator of a poor
outcome for advanced-type NB tumors [1–3,37]. Accumulating
evidence suggests that multiple candidates, including p73, CDH5,
and KIF1b, for genes having a NB-suppressive role within the
1p36-critical region [1–3,38–40]. In addition, some of the 1p
deletions in MYCN-amplified NB tumors are quite large, involving
a proximal segment spanning 1p32–p36; tumors having this
extensive loss of 1p make up a subset of advanced-type NBs with a
poorer prognosis [41,42]. LAPTM5 is mapped at 1p35, not at
1p36, and the copy-number of the LAPTM5 gene locus is also
frequently decreased in NB cell lines (Supplementary Figure
S2). Therefore, the decrease of LAPTM5 gene dosage may also act
to prevent accumulation of LAPTM5-positive vesicles and
LAPTM5-mediated PCD in advanced-type NB tumors with a
large deletion of 1p.
A second key finding is that the cell death mediated by the
accumulation of LAPTM5 protein in NB cells is a lysosomal cell
death with the typical features of lysosomal destabilization through
LMP and with the impaired autophagy in a caspase-independent
manner, as a molecular mechanism for spontaneous regression of
NB tumors. At this time, it is not clear how the accumulated
LAPTM5 contributes to the lysosomal destabilization in degener-
ating NB cells and how the non-accumulated LAPTM5 functions
in differentiating NB cells, adrenal medulla cells, or ganglion cells
in GNs. A recent report demonstrated that LAPTM5 plays an
important role in the lysosomal degradation of specific substrates
in T cells [43]. Therefore, in ‘‘differentiating NB cells’’ or
‘‘matured neuroblastic cells’’ as well as in T cells, LAPTM5 may
also function in the lysosomal degradation system for specific
substrate(s). Our in vitro study showed that LAPTM5 intrinsically
localizes to trafficking vesicles from the Golgi apparatus to the
lysosomes in NB cells, and consecutive overexpression of
LAPTM5 leads to the accumulation of LAPTM5-positive vesicles
together with losses of the Golgi apparatus and punctate pattern of
lysosomes. It has been reported that LAPTM5 contributes to
vesicle trafficking from the Golgi apparatus to lysosome [30]. In
addition, lysosomal membrane proteins such as LAMP1 and
LAMP2 were transported from the Golgi apparatus to the
lysosomes [44]. Therefore, the accumulation of LAPTM5-positive
vesicles may lead to a disruption of intracellular vesicle trafficking
in the Golgi-lysosome pathway, resulting in lysosomal destabiliza-
tion, accompanied by interruption of provision of lysosomal
contents into the lysosomes, in ‘‘degenerating NB cells’’.
Interestingly, a recent report showed that a down-regulation of
lysosomal membrane proteins, LAMP1 and LAMP2, increased
sensitivity to the lysosomal cell death and those accumulation
induced by inhibition of lysosomal proteases contribute to the
resistance to lysosomal cell death [45].
On the other hand, our study also revealed that the lysosomal
disruption by treatment with lysosomal inhibitor led to the
accumulation for these vesicles (by a decrease of removal in the
lysosomes), although LAPTM5-positive vesicles were usually
transported into the lysosomes, and to be degraded. A dysfunction
of proteasomal protein degradation also led to the accumulation of
LAPTM5-positive vesicles. Thus, this protein may be also
degraded by ubiquitin-proteasome system to regulate the produc-
tion of LAPTM5-positive vesicles. Indeed, LAPTM5 protein can
be ubiquitinated by NEDD4, an E3 ubiquitin ligase [30].
This cell death is also characterized by the accumulation of
autophagic vacuoles and ubiquitinated proteins and the occasional
formation of ubiquitin-positive inclusion bodies as occurs in
neurodegenerative diseases (NDs) [46], suggesting that a common
molecular mechanism underlies the degeneration of cells in the
regression of NB tumors and in NDs. We consider the ND-like
features of degenerating NB cells attributable to an interruption of
autophagic flux caused by a loss of intact lysosomes through
LAPTM5-mediated lysosomal destabilization, although we can
not exclude the existence of some other mechanism, given results
of studies where autophagic flux or lysosomal degradation were
genetically disrupted in mice [27,28].
Finally, it has been reported that H-Ras is also highly expressed
in degenerating NB cells and its overexpression can induce
caspase-independent cell death with autophagic vacuoles in NB
cells [12]. However, it has been not clarified whether this cell
death is attributable to an interruption of autophagic flux.
Clarification of the relationship between H-Ras and LAPTM5
in signal transduction will require further examination.
Methods
Cell lines and tumor samples
All 10 human NB cell lines used (GOTO, IMR32, SJ-N-CG,
CHP134, MP-N-MS, KP-N-RT, SK-N-AS, SH-SY5Y, SK-N-
SH, and SK-N-KP) had been established from surgically restricted
tumors, and maintained as described elsewhere. Primary samples
were obtained during surgery from NB patients undergoing tumor
resection at University Hospital, Kyoto Prefectural University of
Medicine from 1986 to 2003, with written consent by the parents
of each patient in the formal style and after approval by the local
ethics committee. Staging was evaluated according to the criteria
of the International Staging System (INSS) [20]. Patients were
treated according to previously described protocols [20]. Tumor
samples were frozen immediately and stored at 280uC until
required.
Cell culture and treatments
All cell lines were grown in RPMI1640 medium supplemented
with 10% FCS, penicillin, and streptomycin. Earle’s Balanced Salt
Solution (EBSS) was from Invitrogen. For treatment with drugs in
cell cultures, wortmannin (Sigma), zVAD-fmk (Peptide Institute),
Bafilomycin A1 (Sigma), ALLN (Calbiochem), NH4Cl (Wako), and
MG-132 (Calbiochem) were used.
Generation of specific antibody for LAPTM5
An anti-LAPTM5 polyclonal antibody against a peptide,
CEEALSLPSKTPEGG, from the carboxyl terminus was gener-
ated in rabbits (Qiagen), and affinity-purified.
DNA methylation analysis
For bisulfite sequencing, genomic DNA was treated with
sodium bisulfite and amplified with primer sets for sequences of
interest. PCR products were sub-cloned and sequenced.
To investigate methylation status in primary tumor samples,
methylation-sensitive single nucleotide primer extension (Ms-
SNuPE) was performed [47]. Genomic regions containing two
CG sites were amplified using sodium bisulfite-treated DNA; the
PCR products were purified from agarose gels and used as
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specific for each site. The MS-SNuPE products were run on 15%
polyacrylamide gels, and the resulting signals were quantified with
a Phosphoimager analysis system (Molecular Dynamics). Methyl-
ation values were calculated based on results from two CG sites,
according to the following equation: [methylated C/(methylated C
+ unmethylated T)]6100. Primer sequences used in the analysis
are provided in Supplementary Table S3.
Reverse Transcription (RT)-PCR
Single-stranded cDNA generated from total RNA [20] was
amplified with a primer set specific for the gene being examined.
Real-time quantitative PCR experiments were done on an ABI-
7900 with TaqMan probes (Applied Biosystems). The gene
encoding glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
served as an endogenous control. Each sample was normalized
on the basis of its GAPDH content. Primer sequences are provided
in Supplementary Table S3.
Immunohistochemistry
Sections from paraffin-embedded tumor samples were depar-
affinized by xylene, and rehydrated in ethanol. After the retrieval
of antigens by boiling in 10 mM citrate buffer (pH 6.0), the
sections were treated with 0.3% hydrogen peroxide in methanol to
inactivate the endogenous peroxidase. Then, the sections were
incubated with an antibody against LAPTM5 (1:200), cleaved
caspase-3 (1:200, Cell signaling), CD20 (BCA-B20; 1:10, kindly
provided by Dr H. Tsuda), p62/SQSTM1 (1:200, Santa Cruz
Biotechnology), ubiquitin (1:200, Dako), or cathepsin D (1:200,
Chemicom) for 1 hour at room temperature. The bound antibody
was visualized using diaminobenzidine as a chromogen (VEC-
TASTAIN
_ Elute ABC kit, Vector Laboratories), and the sections
were lightly counterstained with hematoxylin. The specificity of
LAPTM5 immunostaining was confirmed by omission of the
primary antibody, using rabbit preimmune-serum as the primary
antibody, or by the immunoabsorption method.
Western blotting
Whole-cell extracts were prepared in RIPA buffer containing a
proteinase inhibitor cocktail (Roche). Western blotting was
performed as described previously [20]. Antibodies against
LAPTM5 (1:1000), MYCN (1:500, Santa Cruz Biotechnology),
p62/SQSTM1 (1:1000), ubiquitin (1:1000), ATG5 (1:500, Ab-
gent), LC3B (1:4000, Sigma), b-actin (1:4000, Sigma), and GFP
(1:1000, MBL) were used according to the manufacturer’s
instructions. As an internal control for western blotting, the blots
were stripped and reprobed with a monoclonal antibody against b-
actin (Sigma).
Isolation of cells stably expressing GFP-LC3
The GFP-LC3 expression vector was kindly provided by Dr T.
Yoshimori. Cells were transfected with GFP-LC3 using Lipofec-
toamine 2000 (Invitrogen) according to instructions. Then they
were cultured in the presence of G418 (Sigma) for 3 weeks and the
resistant colonies pooled in a mass were used as the cells stably
expressing GFP-LC3.
Immunofluorescence microscopy
The cells were fixed in 4% formaldehyde or 10% trichloroacetic
acid (TCA), permeabilized with 0.2% Triton X-100 and treated
with blocking solution (1% BSA/0.01% Triton X-100 in PBS),
and then incubated at 37uC with the primary antibody for 3 hours
or overnight. The bound antibody was visualized using a FITC-
conjugated or Alexa Fluor 594-conjugated secondary antibody.
After mounting with DAPI (49,69-diamidino-2-phenylindole) to
stain nuclei, the cells were observed under a fluorescence
microscope (ECLIPSE 800; Nikon) or a conforcal microscopy
(Carl Zeiss). Antibodies against LAPTM5 (1:200), LC3B (1:1000),
p62/SQSTM1 (1:200), ubiquitin (1:200), Golgi-58K (1:200,
Sigma), and cathepsin D (1:200) were used according to the
manufacturers’ recommendations.
RNA interference
The siRNAs for LAPTM5 (siGENOME SMARTpool M-
019880) and for Control (siControl, Non-targeting siRNA #2)
were from Dharmacon. The siRNAs for Luciferase
(CGUACGCGGAAUACUUCGA) and for ATG5 (GCAACU-
CUGGAUGGGAUUG) were from Sigma. The siRNAs were
transfected into cells using Lipofectoamine RNAi MAX (Invitro-
gen) according to the manufacturer’s directions and after 4–
6 hours, the medium was renewed.
Recombinant Adenovirus
The replication-defective recombinant adenovirus was con-
structed with the Adenovirus Expression Vector Kit (Takara)
following the manufacturer’s recommendations. Cosmid vec-
tor-inserted full-length LAPTM5 cDNA (pAxCAwtit-LAPTM5)
was generated and the adenovirus was propagated in HEK293
cells, and stored at 280uC prior to use. As a control, an Ad-
LacZ adenovirus encoding the b-galactosidase gene was
constructed from the cosmid pAxCAiLacZ (TaKaRa). Viral
titers were measured in pfu/ml by a limiting-dilution method
using the HEK293 cells. Cells were infected with each MOI
(multiplicity of infection; PFU/cell). Primer sequences for the
construction of vectors are provided in Supplementary
Table S3.
Cell death and survival assays
For the cell death assay, numbers of dead cells were determined
using the trypan blue exclusion method. A minimum of 100 cells
were counted in each experiment. For cell survival assay, numbers
of viable cells were assessed by a colorimetric water-soluble
tetrazolium salt assay (WST assay, cell counting kit-8; Dojindo
Laboratories).
Electron microscopy
The cells were fixed with 2.5% glutaraldehyde in 0.1 M
phosphate-buffered saline (PBS) overnight. They were washed
with 0.1 M PBS at 4uC and post-fixed with 1% OSO4 buffered in
0.1 M PBS for 2 h. Then the cells were dehydrated in a graded
series of ethanol solutions and embedded in Epon 812. Ultrathin
(90 nm) sections were collected on copper grids, double-stained
with uranyl acetate and lead citrate, and examined by transmission
electron microscopy (H-7100, Hitachi).
LysoTracker Rhodamine (LTR) staining and Acridine
orange (AO) uptake analysis
For LTR staining, the cells were stained with 100 nM of LTR
(Molecular Probes) for 30 min at 37uC. After two washes with
PBS, the cells were analyzed by fluorescence microscopy for LTR.
For AO uptake analysis, the cells were stained with 5 mg/ml of AO
(Sigma) for 30 min at 37uC. Then, detached cells were removed,
attached cells were collected by tripsinization and washed twice
with PBS. The cells untaken AO were detected by flow cytometry
using a FACScan (Becton-Dickinson).
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The results of quantitative in vitro analyses are presented as the
mean and SD. Differences were compared with a two-sided test
(Student’s t-test).
Supporting Information
Methods S1 Supplementary methods and Supplementary
references
Found at: doi:10.1371/journal.pone.0007099.s001 (0.03 MB
DOC)
Table S1 List of BACs containing possibly methylated regions in
NB cell lines compared to PBMNCs by BAMCA analysis a;
Distance from the top of short arm on chromosome 1. b; BAMCA
ratios wereindicatedbyresultingfor duplicate spots (1and 2).c;The
presence (‘‘yes’’) or absence (‘‘no’’) of expression for each gene was
determined by RT-PCR as indicated in Supplementary Figure S1.
d; The presence (‘‘yes’’) or absence (‘‘no’’) of differential methylation
inSmaIsitesforeachgenewas determinedbyMS-PCRasindicated
in supplementary Figure S1. e; The methylation status of LAPTM5
in primary NB tumors was determined by COBRA as indicated in
supplementary Figure S1. ‘‘-’’ indicates ‘‘not tested’’.
Found at: doi:10.1371/journal.pone.0007099.s002 (0.02 MB
DOC)
Table S2 Summary of copy-number aberrations for MYCN,
LAPTM5, and 1p35 region in 13 NB cell lines a; Copy-number
status for MYCN gene locus and 1p35 region was determined by
array-CGH and conventional CGH analysis. ‘‘yes’’ indicates the
presence of MYCN amplification or 1p35 loss, and ‘‘no’’ indicates
the absence of them. b; Two probes were used for FISH analysis.
418B22 (BAC clone), spotted on 1p36-contig array, is mapped on
1p35and contain LAPTM5gene locus.The pUC1.77 (plasmid) asa
control is mapped on the pericentromeric region of chromosome 1.
Found at: doi:10.1371/journal.pone.0007099.s003 (0.02 MB
DOC)
Table S3 Primer sequences
Found at: doi:10.1371/journal.pone.0007099.s004 (0.02 MB
DOC)
Figure S1 Validation of candidate genes down-regulated through
DNA methylation (A) Schematic diagram of BAMCA experiments.
DNA fragments generated by the MCA method from NB cell lines
(Green) and from the references(Red)werelabeled with Cy3 orCy5
respectively, and co-hybridized on the in-house1p35–p36 contig
array. (B) Screening of down-regulated genes by RT-PCR analysis.
GAPDH served as an internal control. Adr, normal adrenal glands;
S1 NBs, pooled samples from five stage-1 NB tumors. (C)
Determination of methylation status of SmaI sites within 418B22,
a BAC clone that includes LAPTM5, by MS-PCR in PBMNCs and
the two NB cell lines GOTO and IMR32. Sixteen primer sets were
used for PCRin genomic regions includingat least two SmaI sites in
a distance range of 200–2,000 bp, because the MCA procedure
produced a genomic fragment having two adjacent methylated
SmaI sites at each end. Black and white circles indicate the presence
(methylated) or absence (unmethylated) of PCR products, respec-
tively. The region (including no. 12–16) shown by a gray box
indicates the NB-specific methylated region at the LAPTM5 locus.
(D) Determination of methylation status at CG sites around the
transcriptional-start site of the LAPTM5 gene by bisulfite
sequencing. A total of 32 CG sites within 1 kb of the start site
were analyzed using two primer sets (regions-I and -II). An arrow at
the start-site shows the direction of transcription. Arrowheads
indicate two SmaI sites that located within the PCR product
produced by no. 14 primers, as indicated in (C). GOTO and
IMR32 cells were both widely methylated, whereas PBMNCs and
an EBV-transformed lymphocyte cell line (LCL) were almost
completely unmethylated.(E)Representative images of COBRA for
LAPTM5 in primary NB tumors. Methylation of this gene was
detected in regions-I and -II in all NB tumors examined. Bisulfite-
PCR products for each of the two regions indicated in (D) were
digested with HinfI (region-I) and TaqI (region-II). Arrows indicate
where bands would show the presence of methylation.
Found at: doi:10.1371/journal.pone.0007099.s005 (0.85 MB TIF)
Figure S2 Analysis of DNA copy-number aberrations in the 1p
region in NB cell lines Frequency of 1p loss in NB cell lines
revealed by array-CGH. In house ‘MCG cancer array-800’-
spotted arbitrary BACs, including 43 BACs on 1p, were used for
analyzing 13 NB cell lines (GOTO, IMR32, SJ-N-CG, CHP134,
MP-N-MS, KP-N-RT, SMS-KCN, SK-N-DZ, SMS-KAN, SK-
N-AS, SH-SY5Y, SK-N-SH, and SK-N-KP). The sideways red (4
non-amplified NB cell lines) or blue (MYCN-amplified NB cell
lines) bars indicate frequencies of loss on each BAC, respectively.
A large range of loss on 1p, including the LAPTM5 locus, was
detected frequently in MYCN-amplified NB cell lines.
Found at: doi:10.1371/journal.pone.0007099.s006 (0.93 MB TIF)
Figure S3 Methylation analysis in primary NB tumors and
ganglioneuromas (GNs) by the methylation-sensitive single-nucle-
otide primer extension (Ms-SNuPE) method (A) Positions of
primers used in the Ms-SNuPE analysis. Bisulfite-PCR products
for region-I (indicated in Supplementary Figure S1) were obtained.
Arrows indicate the position of each primer used in primer-
extension experiments. When a CG site is methylated or
unmethylated, either ‘‘C’’ or ‘‘T’’ is appended, respectively. (B)
Representative image of the Ms-SNuPE analysis at the CG-II site.
Purified bisulfite-PCR products (25 ng), a primer, and radioiso-
tope-labeled C or T were reacted for primer extension; products
were purified and loaded on polyacrylamide gels for electropho-
resis (PAGE). A methylation value for each CG site was computed
using the following equation: methylated C/(methylated C +
unmethylated T)6100. GN sample numbers, T830, T1052, and
T334, reflect GN1, GN2, and GN3 in Figure 1D.
Found at: doi:10.1371/journal.pone.0007099.s007 (0.46 MB TIF)
Figure S4 Representative images from immunohistochemical
staining for LAPTM5, H-Ras, or CD20 (BCA-B20) in degenerating
NB cells within regressing areas in mass-screened NB tumors (A)
Representative images of immunostaining for each protein in
regressing areas within sections from Stage-4S NB tumors detected
by mass-screening. Serial tumor sections were stained with
hematoxylin-eosin (HE) (left), with LAPTM5 (middle), or with H-
Ras antibody (right). Arrowheads indicate a degenerated area. (B)
Representative images of CD20 (BCA-B20) staining in regressing
areas within sections from Stage-1 NB tumors detected by mass-
screening. Arrowheads indicate CD20-positive hematopoietic cells.
Found at: doi:10.1371/journal.pone.0007099.s008 (5.55 MB TIF)
Figure S5 Detection of cleaved caspase-3 during CDDP- or
LAPTM5-induced cell death (A) Representative image of cleaved
caspase-3 staining. The cells (26105/well for CDDP, 16105/well
for infection) were plated on coverslips in 24-well plates, and the
next day treated with Cisplatin (CDDP; 1.5 mg/ml in SH-SY5Y
cells) for 2 days or infected with Ad-LacZ or Ad-LAPTM5 at a
MOI of 10 for 4 days. Cells were fixed, reacted with an antibody
to cleaved caspase-3, and visualized with a Alexa Fluor 594-
conjugated secondary antibody. (B) Quantitation of the percentage
of cleaved caspase-3-positive cells during cell death in NB cell lines
including SH-SY5Y in (A). The percentage of cleaved caspase-3-
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Vertical lines, SD for three experiments. (C) Western blotting for
cleaved caspase-3. The cells were treated as indicated in (A) and
whole-cell lysate was analyzed by immunoblotting with an
antibody to cleaved caspase-3 or b-actin (internal control). (D)
Effect of zVAD-fmk treatment during CDDP-induced cell death in
SH-SY5Y cells. SH-SY5Y (16104/well) cells plated in 96-well
plates were treated with CDDP (1.5 ug/ml) in the absence or
presence of zVAD-fmk (100 mM). The percentage of surviving
cells was determined two days after treatment by WST assay.
Vertical lines, SD for three experiments. *t-test. p,0.05
Found at: doi:10.1371/journal.pone.0007099.s009 (1.16 MB TIF)
Figure S6 Appearance of autophagic vacuoles during LAPTM5-
induced cell death in SH-SY5Y and GOTO cells stably expressing
GFP-LC3 (A) Localization of endogenous LC3B detected by
immunofluorescence microscopy. SH-SY5Y cells (16105/well)
were plated on coverslips in 24-well plates, and the next day
infected with Ad-LacZ or Ad-LAPTM5 at a MOI of 10. Four days
later, the cells were fixed in 10% TCA 4 days after infection,
reacted with the LC3B antibody, and visualized with an Alexa
Fluor 594-conjugated secondary antibody. (B) Detection of LC3
form-II by western blotting. As the time-courses indicated, whole-
cell lysate from SH-SY5Y cells (left) or GOTO cells stably
expressing GFP-LC3 (right) infected with Ad-LacZ and Ad-
LAPTM5 at a MOI of 10 was analyzed by immunoblotting with
an antibody to endogenous LC3B, GFP, or b-actin (internal
control). Arrows indicate form-I or -II of LC3B or GFP-LC3.
Found at: doi:10.1371/journal.pone.0007099.s010 (0.98 MB TIF)
Figure S7 Representative images of the subcellular localization
of GFP-LC3 or endogenous LC3B by immunofluorescence
microscopy GOTO cells stably expressing GFP-LC3 (A) or
parental GOTO cells (B) were prepared and treated as described
in Figure 4B. The number of cells with a GFP-LC3 or LC3B
punctate pattern was decreased by treatment with wortmannin
(Wort.; 200 nM) or knockdown of ATG5 during starvation or
LAPTM5-induced cell death.
Found at: doi:10.1371/journal.pone.0007099.s011 (2.30 MB TIF)
Figure S8 Accumulation of p62/SQSTM1 protein in Ad-
LAPTM5-infected GOTO cells. The accumulation of p62/
SQSTM1 protein in Ad-LAPTM5-infected GOTO cells was
revealed by immunofluorescence microscopy. Four days after
infection, cells were fixed, reacted with an antibody to p62/
SQSTM1, and visualized with Alexa Fluor 594-conjugated
secondary antibody. The images were obtained with different
exposure times (0.2 and 0.02 seconds for Ad-LacZ and Ad-
LAPTM5-infected cells, respectively).
Found at: doi:10.1371/journal.pone.0007099.s012 (0.64 MB TIF)
Figure S9 Subcellular localization of accumulated LAPTM5
during LAPTM5-induced cell death. Representative image of the
co-staining of LAMP2 (Green) and LAPTM5 (Red). GOTO cells
were infected with Ad-LacZ or Ad-LAPTM5 at a MOI of 10 in
medium containing Bafilomycin A1 (Baf.A1, 2 nM) or ALLN
(2 mM) for 2 days. Immunofluorescence microscopy was per-
formed as in Figure 6A. DAPI was counterstained. In GOTO cells
subjected to mild treatment with Baf.A1 or ALN, LAPTM5 was
frequently localized into LAMP2-positive lysosomes.
Found at: doi:10.1371/journal.pone.0007099.s013 (4.81 MB TIF)
Figure S10 Lysosomal membrane permeabilization (LMP) dur-
ing LAPTM5-induced cell death. (A) Frequency of cells with loss of
a punctuate pattern of LTR staining. One or four days after
infection with Ad-LacZ or Ad-LAPTM5, cells that had lost the
punctuate pattern of LTR staining, so-called ‘‘Pale cells’’, were
counted, and the number recorded as a percentage of all cells. The
graph indicates the percentages of cells in both cell lines. Vertical
lines, SD for three separate experiments. *t-test, p,0.001,
**p,0.05. No inf., no infection. (B) Representative images of
staining for FITC-dextran (40 kD) in infected GOTO cells. GOTO
cells (16105/well) were plated on coverslips in 24-well plates, and
the next day infected with Ad-LacZ or Ad-LAPTM5 at a MOI of
10, and then maintained in medium containing 100 mg/ml of
FITC-dextran (40kD). Right; Four days after infection, cells were
washed twice, fixed in 4% formaldehyde, and observed by
fluorescence microscope. Left; The percentage of cells that released
FITC-dextran (40 kD) among cells at least 200 cells was measured.
Vertical lines, SD for three separate experiments. *t-test. p,0.05.
Found at: doi:10.1371/journal.pone.0007099.s014 (1.10 MB TIF)
Figure S11 Detection of GFP-LC3 form-II and accumulation of
p62/SQSTM1 on treatment with Ciprofloxacin (CPX) GOTO
cells stably expressing GFP-LC3 (16106/well) were plated in 6-
well plates, and treated with CPX (100 or 300 mg/ml) for one day.
As a solvent for CPX, 0.1N HCl was added with 1 or 3% of the
medium. Whole-cell lysate from treated cells was analyzed by
immunoblotting with antibodies to the indicated proteins.
Found at: doi:10.1371/journal.pone.0007099.s015 (0.43 MB TIF)
Figure S12 Detection of endogenous LAPTM5 by western
blotting. (A) Relative levels of LAPTM5 mRNA levels during
induction of differentiation in IMR32 cells. Cells were induced to
neuronal differentiation by maintaining in serum-free medium
including retinoic acid (RA,10 mM) for 4 days. The levels of
LAPTM5 mRNA at the indicated days were determined by
quantitative RT-PCR and normalized with each level of GAPDH
mRNA. Vertical lines, SD. (B) Morphological change during RA-
induced differentiation and treatment with lysosomal or protea-
somal inhibitor. IMR32 cells (26106/well) were plated in 10 cm
dishes and maintained in serum-free medium including RA
(10 mM) (SFRA). At 3 days after induction, Baf.A1 (25 nM) or
ALLN (10 mM) were added in medium and then cultured for 1
day. Treatment with SFRA efficiently induced the appearance of
cells with a number of axonal outgrowth in IMR32 cells (a;
parental IMR32 cells and b; differentiated IMR32 cells).
Additional treatment with Baf.A1 (c) or ALLN (d) frequently
induced cell death with a loss of axon. (C) Detection of endogenous
LAPTM5 protein by western blotting. Cells were treated as
indicated in (b). As a positive control for detection, whole-cell
lysate from LCL highly expressing with or without Baf.A1 (10 nM,
1 day) or ALLN (10 mM 1 day) was used. Arrows indicate bands
for endogenous LAPTM5 detected in expected size. TBS buffer
including 0.05% Tween-20 and 1% Casein was used for blocking
and reaction with antibody. Endogenous LAPTM5 was detected
in expected size. Astarisks indicate non-specific bands. The results
shown represent two independent experiments.
Found at: doi:10.1371/journal.pone.0007099.s016 (2.52 MB TIF)
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